Home/Pipeline/Cell Therapy Approach

Cell Therapy Approach

Solid Tumors

DiscoveryActive (Collaboration with ImmunoScape)

Key Facts

Indication

Solid Tumors

Phase

Discovery

Status

Active (Collaboration with ImmunoScape)

Company

Cue Biopharma

About Cue Biopharma

Cue Biopharma is pioneering precision immunotherapies through its proprietary Immuno-STAT™ (Selective Targeting and Alteration of T Cells) platform. The company engineers biologics that mimic natural immune signals to selectively activate or suppress specific T cell populations, offering a targeted approach for autoimmune diseases and cancer. With a leadership team boasting deep experience from Novartis, Johnson & Johnson, and other industry leaders, Cue has secured strategic partnerships with Boehringer Ingelheim and ImmunoScape to advance its pipeline and technology.

View full company profile

Therapeutic Areas

Autoimmune Disease Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active